Pipeline - Pipeline & Programs - Frequency Therapeutics

Pipeline & Programs

Pipeline

Pipeline

Naturally repairing or reversing damage caused by degenerative disease

Frequency is pioneering a new class of small-molecule therapeutics, called Progenitor Cell Activation (PCA), to selectively activate progenitor cells already present within the body to regenerate healthy functional tissues and organs.

Pipeline

Hearing Program

Frequency’s most advanced program, FX-322, is in sensorineural hearing loss (SNHL) where today no therapeutic options exist. SNHL is the most common form of hearing loss, resulting from damage to the hair cells in the inner ear or problems with the nerve pathways that convert sound waves from the inner ear to the brain.

Hair cells are commonly lost due to chronic noise exposure, or as a result of aging, certain viral infections or exposure to ototoxic drugs.

The human ear is incapable of spontaneously restoring lost or damaged hair cells, making hearing loss a permanent condition. FX-322 is designed to treat the underlying cause of SNHL by regenerating hair cells through activation of progenitor cells already present in the cochlea.

FX-322 is a combination of small molecules that is administered through the eardrum into the middle ear where it diffuses into the inner ear.

We believe that FX-322 has the potential to meaningfully improve overall hearing function and enhance quality of life.

Multiple Sclerosis

We are also exploring ways in which our PCA platform may be beneficial in the treatment of multiple sclerosis (MS). Our program focuses on activating progenitor cells in the central nervous system to repair the myelin sheath that protects nerves and may have the potential to reverse damage done by the disease.

MS is a degenerative disease and while there are several FDA-approved, disease-modifying therapies available, there is no cure. The FDA has approved disease-modifying therapies for MS that reduce the immune system attack, which may reduce the number of relapses, delay progression of disability, and limit new disease activity. However, none of these products repair the central nervous system or lead to remyelination of the nerve fibers, and there is no cure for MS.

We have initiated a discovery program in MS after identifying MS as a degenerative disease that has the potential to be treated with small molecules that activate progenitor cells. In 2017 we initiated a relationship with Scripps, where researchers had discovered agents that can activate oligodendrocyte progenitor cells – the cells responsible for making myelin, which is the protective sheath that covers nerve fibers.

We believe that stimulating progenitor cells in the central nervous system to grow oligodendrocytes could potentially reverse the damage caused by the immune system in MS. We are working to identify a product candidate for the treatment of MS, and we plan to submit an IND to the FDA for an MS product candidate in the second half of 2021.